Priyanthi B Gjerde1, Ingrid Dieset2, Carmen Simonsen3, Eva Z Hoseth4, Trude Iversen5, Trine V Lagerberg6, Siv Hege Lyngstad7, Ragni H Mørch8, Silje Skrede9, Ole A Andreassen10, Ingrid Melle11, Vidar M Steen12. 1. NORMENT, K.G. Jebsen Center for Psychosis Research, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway; Dr. Einar Martens Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, 5021 Bergen, Norway. Electronic address: priyanthi.gjerde@uib.no. 2. NORMENT, K.G. Jebsen Centre for Psychosis Research, Oslo University Hospital, 0424 Oslo, Norway. Electronic address: ingrid.dieset@medisin.uio.no. 3. NORMENT, K.G. Jebsen Centre for Psychosis Research, Oslo University Hospital, 0424 Oslo, Norway. Electronic address: c.e.simonsen@medisin.uio.no. 4. NORMENT, K.G. Jebsen Centre for Psychosis Research, Oslo University Hospital, 0424 Oslo, Norway; Division of Mental Health and Addiction, Møre and Romsdal Health Trust, Kristiansund, Norway. Electronic address: e.z.hoseth@medisin.uio.no. 5. NORMENT, K.G. Jebsen Centre for Psychosis Research, Oslo University Hospital, 0424 Oslo, Norway. Electronic address: t.s.j.iversen@medisin.uio.no. 6. NORMENT, K.G. Jebsen Centre for Psychosis Research, Oslo University Hospital, 0424 Oslo, Norway. Electronic address: t.v.lagerberg@medisin.uio.no. 7. NORMENT, K.G. Jebsen Centre for Psychosis Research, Oslo University Hospital, 0424 Oslo, Norway. Electronic address: s.h.lyngstad@medisin.uio.no. 8. NORMENT, K.G. Jebsen Centre for Psychosis Research, Oslo University Hospital, 0424 Oslo, Norway. Electronic address: r.h.morch@medisin.uio.no. 9. NORMENT, K.G. Jebsen Center for Psychosis Research, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway; Dr. Einar Martens Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, 5021 Bergen, Norway. Electronic address: silje.skrede@uib.no. 10. NORMENT, K.G. Jebsen Centre for Psychosis Research, Oslo University Hospital, 0424 Oslo, Norway; Department of Clinical Medicine, University of Oslo, 0424 Oslo, Norway. Electronic address: o.a.adreassen@medisin.uio.no. 11. NORMENT, K.G. Jebsen Centre for Psychosis Research, Oslo University Hospital, 0424 Oslo, Norway. Electronic address: ingrid.melle@medisin.uio.no. 12. NORMENT, K.G. Jebsen Center for Psychosis Research, Department of Clinical Science, University of Bergen, 5021 Bergen, Norway; Dr. Einar Martens Research Group for Biological Psychiatry, Center for Medical Genetics and Molecular Medicine, Haukeland University Hospital, 5021 Bergen, Norway. Electronic address: vidar.martin.steen@helse-bergen.no.
Abstract
BACKGROUND: A potential link between increase in total cholesterol and triglycerides and clinical improvement has been observed during antipsychotic drug treatment in chronic schizophrenia patients, possibly due to drug related effects on lipid biosynthesis. We examined whether changes in serum lipids are associated with alleviation of psychosis symptoms after one year of antipsychotic drug treatment in a cohort of first-episode psychosis (FEP) patients. METHODS: A total of 132 non-affective antipsychotic-treated FEP patients were included through the Norwegian Thematically Organized Psychosis (TOP) project. Data on antipsychotic usage, serum lipids (total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and triglycerides (TG)), body mass index (BMI) and clinical state were obtained at baseline and after 12months. The Positive and Negative Syndrome Scale (PANSS) was used to assess psychotic symptoms. Mixed-effects models were employed to examine the relationship between serum lipids and psychotic symptoms while controlling for potential confounders including BMI. RESULTS: An increase in HDL during one year of antipsychotic treatment was associated with reduction in PANSS negative subscores (B=-0.48, p=0.03). This relationship was not affected by concurrent change in BMI (adjusted HDL: B=-0.54, p=0.02). No significant associations were found between serum lipids, BMI and PANSS positive subscores. CONCLUSION: We found that an increase in HDL level during antipsychotic treatment is associated with improvement in negative symptoms in FEP. These findings warrant further investigation to clarify the interaction between lipid pathways and psychosis.
BACKGROUND: A potential link between increase in total cholesterol and triglycerides and clinical improvement has been observed during antipsychotic drug treatment in chronic schizophreniapatients, possibly due to drug related effects on lipid biosynthesis. We examined whether changes in serum lipids are associated with alleviation of psychosis symptoms after one year of antipsychotic drug treatment in a cohort of first-episode psychosis (FEP) patients. METHODS: A total of 132 non-affective antipsychotic-treated FEP patients were included through the Norwegian Thematically Organized Psychosis (TOP) project. Data on antipsychotic usage, serum lipids (total cholesterol, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol and triglycerides (TG)), body mass index (BMI) and clinical state were obtained at baseline and after 12months. The Positive and Negative Syndrome Scale (PANSS) was used to assess psychotic symptoms. Mixed-effects models were employed to examine the relationship between serum lipids and psychotic symptoms while controlling for potential confounders including BMI. RESULTS: An increase in HDL during one year of antipsychotic treatment was associated with reduction in PANSS negative subscores (B=-0.48, p=0.03). This relationship was not affected by concurrent change in BMI (adjusted HDL: B=-0.54, p=0.02). No significant associations were found between serum lipids, BMI and PANSS positive subscores. CONCLUSION: We found that an increase in HDL level during antipsychotic treatment is associated with improvement in negative symptoms in FEP. These findings warrant further investigation to clarify the interaction between lipid pathways and psychosis.
Authors: Priyanthi B Gjerde; Carmen E Simonsen; Trine V Lagerberg; Nils E Steen; Torill Ueland; Ole A Andreassen; Vidar M Steen; Ingrid Melle Journal: Eur Arch Psychiatry Clin Neurosci Date: 2019-04-27 Impact factor: 5.270
Authors: Amany A Saleh; Nesreen G Elhelbawy; Rania M Azmy; Mohammed S Abdelshafy; Sally S Donia; Eman M Abd El Gayed Journal: Biochem Biophys Rep Date: 2022-02-19